)
Visual
earnings real time
Avecho Biotechnology
Avecho Biotechnology (AVE) investor relations material
Avecho Biotechnology Q3 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 TU earnings summary30 Oct, 2025
Executive summary
Recruitment in the pivotal Phase III CBD TPM® insomnia trial reached 160 patients, with interim analysis results expected in H1 2026.
Three new clinical sites were activated, accelerating recruitment and supporting regulatory milestones.
Collaboration with Sandoz AG led to a revised statistical analysis plan, enhancing trial robustness.
The trial aims to support TGA submission for over-the-counter registration of the CBD TPM® soft-gel capsule for insomnia.
Financial highlights
Cash balance at 30 September 2025 was $4.6 million.
Operational cash outflows for the quarter were $1.33 million, primarily for R&D and trial activities.
Receipts from customers for the quarter totaled $28,000; year-to-date receipts were $6.14 million.
Government grants and tax incentives contributed $652,000 during the quarter.
Payments to related parties and associates totaled $67,000 for the quarter.
Outlook and guidance
Focus remains on completing Phase III trial recruitment and preparing for TGA submission.
$2.5 million capital raise post-quarter will accelerate manufacturing scale-up and regulatory preparations.
International licensing discussions are ongoing, leveraging the Sandoz AG agreement as a benchmark.
Impact of revised statistical analysis
Explain Q3 operating cash flow variance
Update on international licensing discussions
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 386
Profit fell 16% to RMB48.9B, but cost cuts and a 75% payout ratio were maintained. - 386Net profit and revenue fell on lower oil prices and weak margins, despite improved cash flow.
- DNLM
Sales and digital growth, margin expansion, and strategic investments drive strong FY25 results. - DNLMSales up 3.8% to £1,771m, profit before tax £211m, digital sales 40%, market share 7.9%.
- 9412
Profits and equity improved, with upward revisions to full-year forecasts and new subsidiaries added. - NVDA
AI is transforming enterprises by enabling intent-driven innovation and technology-first strategies. - DNLMH1 sales up 3.6% to £926m; digital mix 41%; PBT to hit lower end of consensus.
- CRW
Double-digit growth, strong cash flow, and new leadership drive confidence for FY25. - 7011
Strong revenue and profit growth in FY2025, with raised guidance and key divestiture impact. - 8053
Profit attributable to owners dipped 1.9% despite higher revenues and strong FX gains.
Next Avecho Biotechnology earnings date
Q4 202512 Feb, 2026
Avecho Biotechnology
Next Avecho Biotechnology earnings date
Q4 202512 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Avecho Biotechnology Limited is an Australian pharmaceutical company focused on drug delivery systems. The company develops proprietary formulations that enhance the solubility and absorption of active pharmaceutical ingredients using lipid-based delivery platforms. Its technologies are applied in human health, animal health, and topical therapeutics. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage